These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

207 related articles for article (PubMed ID: 30254436)

  • 21. Combination of 5-fluorouracil and irinotecan on modulation of thymidylate synthase and topoisomerase I expression and cell cycle regulation in human colon cancer LoVo cells: clinical relevance.
    Xu JM; Azzariti A; Tommasi S; Lacalamita R; Colucci G; Johnston PG; Church SW; Paradiso A
    Clin Colorectal Cancer; 2002 Nov; 2(3):182-8. PubMed ID: 12482336
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Preparation of pegylated nano-liposomal formulation containing SN-38: In vitro characterization and in vivo biodistribution in mice.
    Atyabi F; Farkhondehfai A; Esmaeili F; Dinarvand R
    Acta Pharm; 2009 Jun; 59(2):133-44. PubMed ID: 19564139
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of adding the topoisomerase I poison 7-ethyl-10-hydroxycamptothecin (SN-38) to 5-fluorouracil and folinic acid in HCT-8 cells: elevated dTTP pools and enhanced cytotoxicity.
    Mullany S; Svingen PA; Kaufmann SH; Erlichman C
    Cancer Chemother Pharmacol; 1998; 42(5):391-9. PubMed ID: 9771954
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Enhanced therapeutic efficacy of a novel liposome-based formulation of SN-38 against human tumor models in SCID mice.
    Lei S; Chien PY; Sheikh S; Zhang A; Ali S; Ahmad I
    Anticancer Drugs; 2004 Sep; 15(8):773-8. PubMed ID: 15494639
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Cellular pharmacology of the combination of the DNA topoisomerase I inhibitor SN-38 and the diaminocyclohexane platinum derivative oxaliplatin.
    Zeghari-Squalli N; Raymond E; Cvitkovic E; Goldwasser F
    Clin Cancer Res; 1999 May; 5(5):1189-96. PubMed ID: 10353756
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Clinical pharmacokinetics of irinotecan.
    Chabot GG
    Clin Pharmacokinet; 1997 Oct; 33(4):245-59. PubMed ID: 9342501
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Preparation, characterization and in vitro evaluation of sterically stabilized liposome containing a naphthalenediimide derivative as anticancer agent.
    Parise A; Milelli A; Tumiatti V; Minarini A; Neviani P; Zuccari G
    Drug Deliv; 2015; 22(5):590-7. PubMed ID: 24286206
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Optimized thermosensitive liposomes for selective doxorubicin delivery: formulation development, quality analysis and bioactivity proof.
    Levacheva I; Samsonova O; Tazina E; Beck-Broichsitter M; Levachev S; Strehlow B; Baryshnikova M; Oborotova N; Baryshnikov A; Bakowsky U
    Colloids Surf B Biointerfaces; 2014 Sep; 121():248-56. PubMed ID: 25001189
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Determinants of CPT-11 and SN-38 activities in human lung cancer cells.
    van Ark-Otte J; Kedde MA; van der Vijgh WJ; Dingemans AM; Jansen WJ; Pinedo HM; Boven E; Giaccone G
    Br J Cancer; 1998 Jun; 77(12):2171-6. PubMed ID: 9649129
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Liposomalization of SN-38 as active metabolite of CPT-11.
    Sadzuka Y; Takabe H; Sonobe T
    J Control Release; 2005 Nov; 108(2-3):453-9. PubMed ID: 16182400
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Development and evaluation of oxaliplatin and irinotecan co-loaded liposomes for enhanced colorectal cancer therapy.
    Zhang B; Wang T; Yang S; Xiao Y; Song Y; Zhang N; Garg S
    J Control Release; 2016 Sep; 238():10-21. PubMed ID: 27432750
    [TBL] [Abstract][Full Text] [Related]  

  • 32. A phase I and pharmacokinetic study of a powder-filled capsule formulation of oral irinotecan (CPT-11) given daily for 5 days every 3 weeks in patients with advanced solid tumors.
    Pitot HC; Adjei AA; Reid JM; Sloan JA; Atherton PJ; Rubin J; Alberts SR; Duncan BA; Denis L; Schaaf LJ; Yin D; Sharma A; McGovren P; Miller LL; Erlichman C
    Cancer Chemother Pharmacol; 2006 Aug; 58(2):165-72. PubMed ID: 16328416
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Dexamethasone Loaded Liposomes by Thin-Film Hydration and Microfluidic Procedures: Formulation Challenges.
    Al-Amin MD; Bellato F; Mastrotto F; Garofalo M; Malfanti A; Salmaso S; Caliceti P
    Int J Mol Sci; 2020 Feb; 21(5):. PubMed ID: 32111100
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Determinants of the cytotoxicity of irinotecan in two human colorectal tumor cell lines.
    Pavillard V; Agostini C; Richard S; Charasson V; Montaudon D; Robert J
    Cancer Chemother Pharmacol; 2002 Apr; 49(4):329-35. PubMed ID: 11914913
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A novel B-ring modified homocamptothecin, 12-Cl-hCPT, showing antiproliferative and topoisomerase I inhibitory activities superior to SN-38.
    Bailly C; Laine W; Baldeyrou B; Demarquay D; Huchet M; Coulomb H; Lanco C; Lavergne O; Bigg DC
    Anticancer Drug Des; 2001 Feb; 16(1):27-36. PubMed ID: 11762642
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Active transepithelial transport of irinotecan (CPT-11) and its metabolites by human intestinal Caco-2 cells.
    Yamamoto W; Verweij J; de Bruijn P; de Jonge MJ; Takano H; Nishiyama M; Kurihara M; Sparreboom A
    Anticancer Drugs; 2001 Jun; 12(5):419-32. PubMed ID: 11395570
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Two novel camptothecin derivatives inhibit colorectal cancer proliferation via induction of cell cycle arrest and apoptosis in vitro and in vivo.
    Du H; Huang Y; Hou X; Quan X; Jiang J; Wei X; Liu Y; Li H; Wang P; Zhan M; Ai X; Lu L; Yuan S; Sun L
    Eur J Pharm Sci; 2018 Oct; 123():546-559. PubMed ID: 30118848
    [TBL] [Abstract][Full Text] [Related]  

  • 38. pH-responsive and folate-coated liposomes encapsulating irinotecan as an alternative to improve efficacy of colorectal cancer treatment.
    Nunes SS; Miranda SEM; de Oliveira Silva J; Fernandes RS; de Alcântara Lemos J; de Aguiar Ferreira C; Townsend DM; Cassali GD; Oliveira MC; Branco de Barros AL
    Biomed Pharmacother; 2021 Dec; 144():112317. PubMed ID: 34634556
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Pre-clinical evaluation of SN-38 and novel camptothecin analogs against human chronic B-cell lymphocytic leukemia lymphocytes.
    Cohen DP; Adams DJ; Flowers JL; Wall ME; Wani MC; Manikumar G; Colvin OM; Silber R
    Leuk Res; 1999 Nov; 23(11):1061-70. PubMed ID: 10576512
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Neural stem cell-mediated delivery of irinotecan-activating carboxylesterases to glioma: implications for clinical use.
    Metz MZ; Gutova M; Lacey SF; Abramyants Y; Vo T; Gilchrist M; Tirughana R; Ghoda LY; Barish ME; Brown CE; Najbauer J; Potter PM; Portnow J; Synold TW; Aboody KS
    Stem Cells Transl Med; 2013 Dec; 2(12):983-92. PubMed ID: 24167321
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.